

QUARTERLY INVESTMENT REVIEW

International All Country Equity Allocation Strategy

RETURNS (%) (LOCAL)	Cumulative (%)		Annualized (%)				
	QTD	YTD	1 Year	3 Years	5 Years	10 Years	ITD
Net of Fees (Composite)	10.43	20.18	20.18	1.66	6.79	2.84	6.24
Gross of Fees (Composite)	10.63	21.03	21.03	2.40	7.57	3.60	7.04
MSCI ACWI ex USA +	9.75	15.62	15.62	1.55	7.08	3.83	5.29
MSCI ACWI ex USA	9.75	15.62	15.62	1.55	7.08	3.83	5.08
Value Added (vs. MSCI ACWI ex USA +)	0.68	4.57	4.57	0.11	-0.30	-0.99	+0.95
Value Added (vs. MSCI ACWI ex USA)	0.68	4.57	4.57	0.11	-0.30	-0.99	+1.16

Major Performance Drivers

- Top-down asset allocation had a minor negative impact for the quarter, as the overweight position in Emerging Market equities underperformed.
- Security selection was positive, driven by an excellent relative return in Emerging Markets.

Emerging equities, with an emphasis on undervalued stocks within attractively valued countries/sectors, represented 37.3% of the total portfolio weight on average during the quarter. Our overweight position in emerging equities detracted from relative performance as the MSCI Emerging Market index returned 7.9%, well behind the MSCI ACWI ex USA return of 9.8%, although the MSCI Emerging Market ex-China index returned a much more impressive 13.0%. Security selection had a significant positive impact, as the broad Emerging Market exposure returned 13.7% and the Emerging Market ex-China portfolio returned 16.1%. Overweight positions in Anglo American Platinum (South Africa Materials), LARGAN Precision (Taiwan Information Technology), and Kumba Iron Ore (South Africa Materials), along with an underweight position in Alibaba (China Consumer Discretionary) featured in the top five biggest individual contributors to relative performance at the total portfolio level. On the flipside, an overweight position in China Feihe (China Consumer Staples) featured in the five biggest individual detractors from relative performance for the quarter.

Developed ex-U.S. equities accounted for an average weight of 61.9% of the portfolio for the quarter, including the dedicated Japan Value position. This underweight position in Developed ex-U.S. had a small negative impact on relative performance as Developed Markets beat Emerging Markets. Security selection within Developed Markets was challenging for the quarter and the portfolio returned 8.4% in aggregate. An overweight position in 3i Group (U.K. Financials) featured in the top five biggest individual contributors to relative performance at the total portfolio level. On the flipside, overweight positions in Sanofi (France Health Care), BAT (U.K. Consumer Staples), and Ahold (Netherlands Consumer Staples), along with an underweight position in ASML (Netherlands Information Technology) featured in the five biggest individual detractors from relative performance for the quarter.

Portfolio weights, as a percent of equity, for the positions mentioned were: Anglo American Platinum (1.0%), LARGAN Precision (0.8%), Kumba Iron Ore (0.8%), Alibaba (0.0%), China Feihe (0.7%), 3i Group (1.3%), Ahold (1.1%), ASML (0%), Sanofi (1.4%), and BAT (1.3%).

Inception Date: 28-Feb-94

Risks: Risks associated with investing in the Strategy may include Market Risk - Equities, Non-U.S. Investment Risk, Management and Operational Risk, Currency Risk, and Derivatives and Short Sales Risk. Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit www.gmo.com. **Performance Returns:** Performance data quoted represents past performance and is not predictive of future performance. Net returns are presented after the deduction of a model advisory fee and incentive fee if applicable. These returns include transaction costs, commissions and withholding taxes on foreign income and capital gains and include the reinvestment of dividends and other income, as applicable. Fees paid by accounts within the composite may be higher or lower than the model fees used. **GMO LLC claims compliance with the Global Investment Performance Standards (GIPS®).** A Global Investment Performance Standards (GIPS®) Composite Report is available on GMO.com by clicking the GIPS® Composite Report link in the documents section of the strategy page. GIPS® is a registered trademark owned by CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein. Actual fees are disclosed in Part 2 of GMO's Form ADV and are also available in each strategy's Composite Report. Gross returns are presented gross of management fees and any incentive fees if applicable. These returns include transaction costs, commissions, withholding taxes on foreign income and capital gains and include the reinvestment of dividends and other income, as applicable. If management and incentive fees were deducted performance would be lower. For example, if, before fees, the strategy were to achieve a 10% annual rate of return above its hurdle rate each year for ten years, and an annual advisory fee of 1% and incentive fee of 20% of net returns above the hurdle rate were charged during that period, the resulting average annual net return (after the deduction of management and incentive fees) would be approximately 7.20%.

QUARTERLY INVESTMENT REVIEW

PRODUCT OVERVIEW

The Strategy seeks to generate total return greater than that of the MSCI All Country World ex-U.S. Index.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value, but mean reverts to appropriate valuation levels over the long term. Using GMO's 7-Year Asset Class Forecasts, the Strategy seeks to allocate to areas of the global equity markets we believe are most attractively valued. Our approach combines the best of GMO's top-down Asset Allocation views and bottom-up equity research to identify mispricings at both the asset class and individual security levels. The Strategy allocates to equity strategies that are actively managed by other GMO investment teams with expertise and experience in security selection within their respective markets.

IMPORTANT INFORMATION

Benchmark(s): The MSCI ACWI ex USA + Index is an internally maintained benchmark computed by GMO, comprised of (i) GMO blended benchmark of International All Country Equity Allocation Composite through 6/30/2014 and (ii) MSCI ACWI ex USA Index (MSCI Standard Index Series, net of withholding tax) thereafter. The GMO blended benchmark of International All Country Equity Allocation Composite is comprised of a weighted average of account benchmarks; many of the account benchmarks consist of MSCI ACWI (All Country World) ex-U.S. Index (MSCI Standard Index Series, net of withholding tax) or some like proxy for each market exposure they have. For each underlying account benchmark, the weighting of each market index will vary slightly. The index is internally blended by GMO and maintained on a monthly basis. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. The MSCI ACWI ex USA Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international (excluding U.S. and including emerging) large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

The above information is based on a representative account in the Strategy selected because it has the fewest restrictions and best represents the implementation of the Strategy.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SINGAPORE

SYDNEY

TOKYO*

*Representative Office

www.GMO.com